tirzepatide eligibility
Unlock Weight Secrets Tirzepatide or Semaglutide?
35% more patients now qualify for tirzepatide under the 2026 EASO update, while semaglutide’s expanded cardiac label widens its use; both agents offer distinct pathways to weight loss and metabolic control. Understanding the new eligibility thresholds, efficacy data, and safety trade-offs helps clinicians decide which GLP-1 drug best matches